Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Weiss

Psychiatry San Antonio, TX Medical Doctor

NPI 1063414928 CMS profile 47424

8122 Datapoint Dr, Suite 1010, San Antonio, TX 78229

Open in the dashboard

General payments

$744,180

1,230 records reported · program years 2019–2025

Research payments

$2,809

Paid to them · 19 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$333,816 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Thomas Weiss of San Antonio, TX is reported in the CMS Open Payments database as having received $744,180 across 1,230 general payments and $2,809 in research payments paid to them. Separately, studies naming them as principal investigator received $333,816 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,159 84
2024 General $67,289 97
2023 General $190,964 281
2022 General $150,102 215
2021 General $95,037 155
2020 General $61,177 120
2020 Research $1,790 12
2019 General $119,451 278
2019 Research $1,018 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Weiss
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Thomas Weiss were reported at $60,159. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Thomas Weiss Psychiatry median Middle half National median
2019 $119,451 $184 $59–$605 $163
2020 $61,177 $119 $36–$372 $114
2021 $95,037 $143 $43–$576 $132
2022 $150,102 $153 $50–$590 $149
2023 $190,964 $170 $56–$651 $160
2024 $67,289 $179 $57–$673 $164
2025 $60,159 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $422,866 615 payments
  2. Allergan Inc. $157,988 352 payments
  3. Axsome Therapeutics, Inc. $97,958 136 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $23,885 40 payments
  5. Eisai Inc. $19,250 37 payments
  6. Vanda Pharmaceuticals Inc. $11,059 17 payments
  7. Idorsia Pharmaceuticals US Inc $10,101 14 payments
  8. Teva Pharmaceuticals USA, Inc. $254 4 payments
  9. ITI, Inc. $250 4 payments
  10. Otsuka America Pharmaceutical, Inc. $247 2 payments
  11. Other $321 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $568,220 299 payments
  2. Travel and Lodging $75,763 480 payments
  3. Consulting Fee $57,250 24 payments
  4. Honoraria $28,116 18 payments
  5. Food and Beverage $14,751 406 payments
  6. Education $78 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $394,214 576 payments
  2. VRAYLAR Neuroscience $186,640 391 payments
  3. Auvelity $97,930 135 payments
  4. Trintellix $23,761 36 payments
  5. Dayvigo $19,250 37 payments
  6. FANAPT $11,059 17 payments
  7. QUVIVIQ $10,101 14 payments
  8. CAPLYTA $250 4 payments
  9. REXULTI $247 2 payments
  10. Austedo XR $139 2 payments
  11. Other $496 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $1,790 12 payments
  2. AbbVie, Inc. $1,018 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

120

Median for Psychiatry & Neurology: 100

Drug cost

$1,951

Median for Psychiatry & Neurology: $2,986

Branded share of claims

15.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 15 $526
Escitalopram Oxalate Generic 35 $357
Duloxetine Hcl Generic 14 $308
Clonazepam Generic 12 $288
Bupropion Xl Bupropion Hcl Brand 19 $273
Olanzapine Generic 11 $116
Quetiapine Fumarate Generic 14 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$39,906 — —
Auvelity
$27,096 — —
Austedo XR
$139 — —
FANAPT
$121 — —
Sunosi
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record